Top Story Today
One Cancer Drug, $15 Billion, Zero Acquisitions Required
AstraZeneca is reportedly negotiating a roughly $15 billion licensing deal with Summit Therapeutics for ivonescimab, a bispecific antibody that nearly doubled Keytruda's progression-free survival in a head-to-head lung cancer trial. Not an acquisition, not a merger; just the rights to sell one molecule. The drug hits two targets at once (PD-1 and VEGF), stripping tumors of their immune camouflage while cutting off their blood supply. If the deal closes, it would rank among the largest licensing agreements in pharma history.
Why it matters: This deal reflects a new era in oncology dealmaking where bispecific antibodies with strong lung cancer data command prices previously reserved for full company acquisitions, and where beating Keytruda head-to-head turns an unknown company into the hottest ticket in pharma.
Read more →Deals and M&A
Merck KGaA Drops $11.3 Billion on the Toolmaker Behind Your Favorite Lab
Merck KGaA (the German one, not the New Jersey one) is buying Bio-Techne for $11.3 billion in cash, its biggest deal since Sigma-Aldrich. Bio-Techne sells over 500,000 research products across reagents, spatial biology instruments, and diagnostics. The 36% premium signals Merck wants to own the full research-to-clinic workflow, especially in cell therapy and proteomics.
Read more →Lilly's 10th Acquisition of 2026 Is a $2.9 Billion Bet on Precision Immunology
Eli Lilly is paying up to $2.875 billion for Merida Biosciences, a four-year-old startup with a Phase 1 drug that selectively destroys disease-causing antibodies while leaving the rest of the immune system intact. It's Lilly's 10th deal of 2026, part of a deliberate strategy to reinvest GLP-1 profits across immunology, oncology, and neuroscience before competitors catch up.
Read more →Roche Bets $2.3 Billion That the Future of Weight Loss Is About Muscle, Not Just Fat
Roche struck a $2.3 billion deal with Hanmi Pharmaceutical for HM17321, a first-in-class drug that targets a completely different pathway than GLP-1s. In animal studies, it reduced fat while building lean muscle. Still Phase 1, but the strategic logic is clear: Roche isn't trying to out-Lilly Lilly. It's redefining what a good weight-loss outcome looks like.
Read more →GE HealthCare Eyes $1 Billion Deal to Own Both the Scanners and the Molecules
GE HealthCare is reportedly in talks to acquire Sofie Biosciences, a radiopharmaceutical developer, for roughly $1 billion. Sofie makes the radioactive tracers that light up cancer on PET scans. Owning both the cameras and the film would give GE a razor-and-blade model in the booming theranostics space.
Read more →Clinical and Regulatory
The FDA Wants to Shave a Year Off Getting Drugs Into Humans
The FDA launched Operation TrialBlazer, a pilot program that lets sponsors file IND applications in pieces and run startup steps in parallel instead of sequentially. The goal: cut six to twelve months off the path to first-in-human dosing. Eight to ten sponsor-institution pairings will be selected, with applications due October 30. Skeptics note the real bottlenecks (site activation, contracting) may sit outside FDA's control.
Read more →Lutathera Just Got Its First Generic. Nuclear Medicine Will Never Be the Same.
The FDA cleared Bexlutry, the first-ever radioligand equivalent, approved via the 505(b)(2) pathway as an alternative to Novartis' $816-million-a-year Lutathera. Manufacturer Curium pulled off what the industry assumed was years away: proving that even drugs made with decaying radioactive isotopes and hot-cell manufacturing can be replicated. Every company building a radioligand therapy just got a pricing reality check.
Read more →Science and Discovery
The First Fully AI-Designed Drug Just Entered Its Make-or-Break Trial
Insilico Medicine's rentosertib, a drug where AI identified the target and designed the molecule from scratch, just entered a 320-patient Phase 3 trial for pulmonary fibrosis. Phase 2 showed patients' lung function actually improved (a rarity in this disease). If the pivotal trial works, it validates an entire technology. If it fails, the AI drug discovery hype gets a cold shower.
Read more →Sionna's $330 Million Cystic Fibrosis Bet Just Collapsed
Sionna Therapeutics cut 46% of its staff after its lead CF drug produced results indistinguishable from placebo. The company is pivoting to a backup combination, but it went from a multi-program shop to a one-bet company overnight. The failure highlights how brutally hard it is to improve on Vertex's Trikafta, which already works for 90% of CF patients.
Read more →